

Table S1. Percentage of participants who demonstrated cognitive impairment stratified by disease duration.

	Total sample	0–4 years	5–10 years	>10 years	<i>p</i>-value^a
Number of participants (N)	N=224	N=70	N=53	N=101	
Cognitive tests	<i>Percentage (%)</i>	<i>Percentage (%)</i>	<i>Percentage (%)</i>	<i>Percentage (%)</i>	
COWAT	22.8	22.9	18.9	24.8	.71
JOLO	9.0	7.1	5.8	12.1	.35
CVLT-TL	10.7	7.1	9.4	13.9	.36
CVLT-DR	26.0	18.6	24.5	32.0	.14
BVMT-TL	31.5	27.1	30.2	35.4	.51
BVMT-DR	31.5	20.0	20.8	45.5	<.01
SDMT	45.5	31.9	48.1	53.5	.02
PASAT_3sec	45.8	54.4	28.8	48.9	.02
PASAT_2sec	41.2	42.2	30.0	47.1	.15
D-KEFS corsor	5.9	4.3	1.9	9.0	.17
D-KEFS sordesc	5.4	4.3	3.8	7.0	.64

^aChi-square analyses between the three disease duration groups (0–4 years, 5–10 years, >10 years).

Table S2. Comparison of participants with and without EDSS scores and cognitive data.

	Sample w/o EDSS		Sample with EDSS		p-value
Number of participants (N)	N=149		N=315		
Characteristic	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>	
Age (years)	48.32	11.83	45.48	11.42	.01
	<i>Percentage (%)</i>		<i>Percentage (%)</i>		
Female	59.06		73.65		<.01
	<i>Median</i>	<i>IQR</i>	<i>Median</i>	<i>IQR</i>	
EDSS ^a	N/A	N/A	2.5	1.5-3.5	—
<i>Disease course (RMS vs. PMS)</i>	<i>Percentage (%)</i>		<i>Percentage (%)</i>		.01
RRMS	53.02		70.16		—
SPMS	20.13		13.02		—
PPMS	9.40		8.57		—
Unspecified	17.45		8.25		—
<i>Any disease-modifying therapy</i>	51.68		61.59		.04
<i>Any psychotropic treatment</i>	67.11		65.40		.72
<i>Any psychotherapy</i>	8.72		14.92		.06
	Sample w/o Cog. Data		Sample with Cog. Data		
Number of participants (N)	N=240		N=224		
Characteristic	<i>M</i>	<i>SD</i>	<i>M</i>	<i>SD</i>	
Age (years)	48.00	12.59	44.67	10.23	<.01
	<i>Percentage (%)</i>		<i>Percentage (%)</i>		
Female	65.83		72.32		.13
	<i>Median</i>	<i>IQR</i>	<i>Median</i>	<i>IQR</i>	
EDSS ^a	2.5 ^b	1.5 – 4.0	2.0 ^c	1.5 – 3.4	.25
<i>Disease course (RMS vs. PMS)</i>	<i>Percentage (%)</i>		<i>Percentage (%)</i>		<.01
RRMS	55.83		74.11		—
SPMS	18.75		11.61		—
PPMS	9.58		8.04		—
Unspecified	15.83		6.25		—
<i>Any disease-modifying therapy</i>	53.75		63.39		.04
<i>Any psychotropic treatment</i>	66.25		65.63		.89
<i>Any psychotherapy</i>	11.25		14.73		.26

^aOrdinal measure and thus, data reported with non-parametric statistical measures (median and interquartile range).

^bSample size of 147 participants with available EDSS scores.

^cSample size of 168 participants with available EDSS scores.